Pat Toomey Journalist Profile

Articles

Opinion | About Trump’s ‘Reciprocal’ Tariffs

Oct 27, 2024 | wsj.com | Pat Toomey

Donald Trump recently declared that only stupidity could explain my opposition to his reciprocal-tariff proposals. There are other explanations. Concern for Americans’ jobs and standard of living comes to mind. I understand the emotional appeal of trade-rules reciprocity—it satisfies an urge for revenge. But that revenge will be less satisfying for the working-class Americans facing unemployment and higher prices if Mr. Trump carries through on his import-tax promises.
If Based on Merit, the FTC Should Lose PBM Suit

Oct 18, 2024 | townhall.com | Pat Toomey

FTC Chairwoman Lina Khan, with her fellow Democratic Commissioners, recently filed a suit against the leading PBMs in an effort to undermine, or even prohibit, their use of rebates to secure savings in the prescription drug supply chain. In a September 25, 2024 editorial, The Wall Street Journal notes that if the FTC is successful, it will result in higher drug costs for American consumers.
Opinion | If Republicans Don’t Win, Get Ready for a Tax Hike

Jul 24, 2024 | wsj.com | Mike Pence |Pat Toomey

An error occurred. Please try again later. The 2017 Tax Cuts and Jobs Act isn’t broken and doesn’t need fixing. But many of its provisions are set to expire in 2025—and Democrats are threatening to let it happen. That would deliver a serious blow to the U.S. economy and undermine the economic gains the legislation prompted. Recall what Donald Trump inherited in 2017. The economy remained weak almost a decade after the 2008-09 financial crisis.
Biden FTC Distorts Cost-Saving Role of Pharmacy Benefit Managers

Jul 24, 2024 | townhall.com | Pat Toomey

The Federal Trade Commission (FTC) under the Biden administration has once again proven itself focused on maligning market forces in our economy rather than the facts or the wellbeing of consumers. A recent Commission report on pharmacy benefit managers (PBMs) is the latest installment of an agenda designed to justify the further erosion of market forces in our health care system. The Commission’s unbalanced and unempirical report strongly implies scale is inherently harmful. The opposite is true.
Policy Lab | Paradigm Policy

May 15, 2024 | policy.paradigm.xyz | Paul Ryan |Pat Toomey |John Ratcliffe |Marta Belcher

Steve Israel Former U.S. Representative (D-NY) and former chair of the Democratic Congressional Campaign Committee John Ratcliffe Former Director of National Intelligence and former U.S. Representative (R-TX) Marta Belcher Special Counsel at the Electronic Frontier Foundation Deb Callahan Former President of the League of Conservation Voters Makan Delrahim Partner, Latham & Watkins LLP; Former U.S. Assistant Attorney General, U.S. Department of Justice Antitrust Division Nicole Elam President...
GOP can't afford to start 2024 with giant health care mandates

Jan 24, 2024 | washingtontimes.com | Pat Toomey

OPINION: Giant, must-pass bills are the most loved and hated of all legislation: loved because they are often the mules that carry certain legislators’ favorite bills that can’t pass by themselves, hated by other legislators for the same reason (in addition to their usually enormous size, lack of transparency and, typically, immunity from amendments).
Why Congress Should Stay Out of the Credit Card Industry

Dec 11, 2023 | townhall.com | Pat Toomey

President Reagan famously said that the most terrifying words in the English language are, “I’m from the government and I’m here to help.” Likewise, when Congress threatens to “inject more competition in an industry,” skepticism should be our first response. Some in congress are threatening just that with legislation to overturn the credit card industry called the Credit Card Competition Act.
Before Targeting PBMs, Republicans Should Consider the Unintended Consequences

Nov 13, 2023 | townhall.com | Pat Toomey

Over the course of 18 years serving in Congress, I’ve seen that policies can sound good but have negative, unintended consequences. This is especially true in the healthcare industry where Congress is considering proposals that would limit a market-based mechanism that lowers the costs of prescription drugs. Specifically, members are proposing to restrict how pharmacy benefit managers (PBMs) negotiate savings for their clients and get compensated for their work.
‘No Trade Is Free’ Review: A ‘Common Good’ That Isn’t

Sep 20, 2023 | wsj.com | Pat Toomey

Robert Lighthizer, U.S. trade representative under President Trump, believes that America’s persistent trade deficits—imports exceeding exports—arise ultimately from unfair trade policies, were exacerbated by the post-1990s trade agreements, and are leading to economic ruin. In “No Trade Is Free,” he defends the Trump administration’s protectionist policies that were meant to restore balance.